Prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis
Pooled resultResult — go to the resultRelative risk 0.82 95% CI 0.70–0.96Authors' conclusion
Prolonged intravenous infusion of beta-lactam antibiotics in patients with sepsis was associated with short-term survival benefits and higher clinical cure.
Study context
- Population
- Patients with sepsis
- Participants
- 1,762 patients · 9 studies
- Comparison
- Prolonged vs intermittent IV infusion of β-lactam antibiotics
- Outcome
- All-cause mortality
- Follow-up
- Within 30 days
Methodological detailstrial sequential analysis, prospectively registered
- Trial sequential analysis
- Prospectively registered
Pooled result
As reported in the abstract
Relative risk
0.82
95% CI 0.70–0.96
P = 0.01
Prolonged vs Intermittent
RR 0.82 (95% CI 0.70–0.96); P = 0.01
Further pooled results
Hospital mortality, ICU mortality, clinical cure
- Prolonged infusion associated with lower hospital and ICU mortality and higher clinical cure
90-day mortality, emergence of resistant bacteria
- No significant reduction between the two groups
Original publication
Prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. Ann Intensive Care. Published 5 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →